TY - JOUR
T1 - A New Prognostic Index (CLIPI) for Advanced Cutaneous Lymphoma Enables Precise Patient Risk Stratification
AU - Scarisbrick, Julia J
AU - Quaglino, Pietro
AU - Whittaker, Sean J
AU - Bagot, Martine
AU - Guenova, Emmanuella
AU - Papadavid, Evangelia
AU - Prince, H Miles
AU - Sanches, Jose Antonio
AU - Miyashiro, Denis
AU - Servitje, Octavio
AU - Querfeld, Christiane
AU - Akilov, Oleg E
AU - Arumainathan, Arvind
AU - Bennett, Luke
AU - Battistella, Maxime
AU - Benstead, Kim
AU - Berti, Emilio Francesco
AU - Beylot-Barry, Marie
AU - Busschots, Anne-Marie
AU - Cowan, Richard Andrew
AU - Dummer, Reinhard
AU - Dunnill, Giles
AU - Estrach, Maria Teresa
AU - Evison, Felicity
AU - Bashir, Abraham Ellahi
AU - Geskin, Larisa J
AU - Gru, Alejandro
AU - Guitart, Joan
AU - Herrera, Melba C
AU - Hodak, Emmilia
AU - Horwitz, Steven M
AU - Jonak, Constanze
AU - Klemke, Claus-Detlev
AU - Knobler, Robert
AU - McKay, Pamela
AU - Marschalkó, Marta
AU - Massone, Cesare
AU - Matin, Rubeta
AU - Mitteldorf, Christina
AU - Novoa, Roberto Andres
AU - Ortiz-Romero, Pablo L
AU - Pimpinelli, Nicola
AU - Pujol, Ramon M
AU - Ranki, Annmari
AU - Vankeva, Liisa
AU - Rieger, Kerri E
AU - Stadler, Rudolf
AU - Trautinger, Franz
AU - Latzka, Johanna
AU - Vermeer, Maarten H
AU - Wachsmuth, Rachel
AU - Weatherhead, Sophie
AU - Wehkamp, Ulrike
AU - Wobser, Marion
AU - Kim, Youn H
N1 - Copyright © 2025 American Society of Hematology.
PY - 2025/10/2
Y1 - 2025/10/2
N2 - Advanced mycosis fungoides (MF) and Sézary syndrome (SS) have a poor prognosis with overall survival <5 years. Studies have found the current clinical staging (IA-IVB) inadequate for risk stratification. Developing a prognostic index in MF/SS will identify patients with poor outcomes and may allow better management decisions and improved survival.PROCLIPI (Prospective Cutaneous Lymphoma International Prognostic Index) Study was launched in 2015 at 46 international expert MF/SS Centers, prospectively collecting pre-defined datasets in newly diagnosed MF/SS patients to determine a cutaneous lymphoma IPI (CLIPI).552 advanced stage MF/SS patients were recruited. The 5-year overall survival (OS) was IIB=50.0%, IIIA=64.8%, IIIB=43.9%, IVA1=50.8%, IVA2=25.9%, IVB=36.9%. Factors at diagnosis associated with a significantly worse survival were N3 status; p<0.001, age>60yrs; p<0.001, raised serum lactate dehydrogenase; p=0.005 and large-cell transformation in skin; p=0.006. Modelling these 4 independent risk-factors into a CLIPI found there was a statistically significant worse OS in high-versus low-risk p<0.001, high-versus intermediate-risk p=0.002 as well as intermediate-versus low-risk p=0.010. 5 Year OS were 63.3%, 44.7% and 18.3% in the low-, intermediate- and high-risk PROCLIPI cohort respectively.In advanced stage MF/SS there was a low 5-year survival rate and increasing stage was not associated with worsening survival. The use of CLIPI to stratify patients into low, intermediate, and high-risk prognostic groups has the potential to improve patient outcomes by helping guide optimal treatment selection. CPMS ID 17662 (PROCLIPI), RRK4970, ClinicalTrials.Gov ID: NCT02848274.
AB - Advanced mycosis fungoides (MF) and Sézary syndrome (SS) have a poor prognosis with overall survival <5 years. Studies have found the current clinical staging (IA-IVB) inadequate for risk stratification. Developing a prognostic index in MF/SS will identify patients with poor outcomes and may allow better management decisions and improved survival.PROCLIPI (Prospective Cutaneous Lymphoma International Prognostic Index) Study was launched in 2015 at 46 international expert MF/SS Centers, prospectively collecting pre-defined datasets in newly diagnosed MF/SS patients to determine a cutaneous lymphoma IPI (CLIPI).552 advanced stage MF/SS patients were recruited. The 5-year overall survival (OS) was IIB=50.0%, IIIA=64.8%, IIIB=43.9%, IVA1=50.8%, IVA2=25.9%, IVB=36.9%. Factors at diagnosis associated with a significantly worse survival were N3 status; p<0.001, age>60yrs; p<0.001, raised serum lactate dehydrogenase; p=0.005 and large-cell transformation in skin; p=0.006. Modelling these 4 independent risk-factors into a CLIPI found there was a statistically significant worse OS in high-versus low-risk p<0.001, high-versus intermediate-risk p=0.002 as well as intermediate-versus low-risk p=0.010. 5 Year OS were 63.3%, 44.7% and 18.3% in the low-, intermediate- and high-risk PROCLIPI cohort respectively.In advanced stage MF/SS there was a low 5-year survival rate and increasing stage was not associated with worsening survival. The use of CLIPI to stratify patients into low, intermediate, and high-risk prognostic groups has the potential to improve patient outcomes by helping guide optimal treatment selection. CPMS ID 17662 (PROCLIPI), RRK4970, ClinicalTrials.Gov ID: NCT02848274.
UR - https://www.scopus.com/pages/publications/105015104293
U2 - 10.1182/blood.2025029628
DO - 10.1182/blood.2025029628
M3 - Article
C2 - 40663780
SN - 1528-0020
VL - 146
SP - 1687
EP - 1692
JO - Blood
JF - Blood
IS - 14
ER -
SDG 3 – Gute Gesundheit und Wohlergehen